FcγRIIB specific antibodies and methods of use thereof
First Claim
1. An antibody including six CDRs from antibody produced by mouse clone 2B6, having ATCC Accession No. PTA-4591, or an antigen-binding fragment thereof, wherein said antibody is chimeric or humanized of the mouse monoclonal antibody, and wherein said antibody or said antigen-binding fragment thereof comprises a variable domain that specifically binds the extracellular domain of Fcγ
- RIIB with greater affinity than said variable domain binds Fcγ
RIIA.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
-
Citations
29 Claims
-
1. An antibody including six CDRs from antibody produced by mouse clone 2B6, having ATCC Accession No. PTA-4591, or an antigen-binding fragment thereof, wherein said antibody is chimeric or humanized of the mouse monoclonal antibody, and wherein said antibody or said antigen-binding fragment thereof comprises a variable domain that specifically binds the extracellular domain of Fcγ
- RIIB with greater affinity than said variable domain binds Fcγ
RIIA. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
- RIIB with greater affinity than said variable domain binds Fcγ
-
18. A pharmaceutical composition comprising:
-
(A) a therapeutically effective amount of an antibody including six CDRs from antibody produced by mouse clone 2B6, having ATCC Accession No. PTA-4591, or an antigen-binding fragment thereof, wherein said antibody is chimeric or humanized of the mouse monoclonal antibody, and wherein said antibody or said antigen-binding fragment thereof comprises a variable domain that specifically binds the extracellular domain of Fcγ
RIIB with greater affinity than said variable domain binds Fcγ
RIIA; and(B) a pharmaceutically acceptable carrier. - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification